Lexaria Bioscience Corp.
156 Valleyview Road
About Lexaria Bioscience Corp.Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
CEO: Chris Bunka
FOLLOW LEXARIA BIOSCIENCE:
Tweets by Lexaria Bioscience
86 articles about Lexaria Bioscience Corp.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs.
Lexaria Bioscience Corp. announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been successfully completed with positive safety and efficacy findings.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer.
Lexaria Bioscience Corp. announces positive findings in an animal study evaluating DehydraTECH TM processing of the phosphodiesterase inhibitor.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, comments on an independent January 10 study, available here, that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants".
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4.
Lexaria Bioscience Corp. announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week.
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Lexaria Bioscience Corp. is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECH TM -processed cannabidiol reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise.
Lexaria Bioscience Corp. announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD for potentially treating hypertension and heart disease.
Lexaria Bioscience Corp. has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity
Lexaria Bioscience Corp. is pleased to announce that its recent oral tetrahydrocannabinol absorption study THC-A21-1 revealed that DehydraTECH TM -THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.
Lexaria Bioscience Corp. announces today that Chairman & CEO Chris Bunka will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13-15, 2021.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced it is formally beginning the process towards an Investigational New Drug application filing with the Food and Drug Administration with its DehydraTECH-processed cannabidiol as a prospective registered pharmaceutical treatment for hypertension.
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
Lexaria Bioscience Corp. is extremely pleased to issue initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH TM -processed cannabidiol for potential application against hypertension.
Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce the receipt of US$3,817,643 from the exercise of share purchase warrants.
Lexaria Bioscience Corp. is pleased to review its successful 2021 antiviral drug program to date and summarize expected next steps.